ONO 7268MX2 - Ono Pharmaceutical

Drug Profile

ONO 7268MX2 - Ono Pharmaceutical

Alternative Names: ONO7268MX2; Peptide-based cancer vaccine - OncoTherapy Science/Ono Pharmaceutical

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoTherapy Science
  • Developer Ono Pharmaceutical
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatocellular carcinoma

Most Recent Events

  • 28 Jul 2017 Discontinued - Phase-I for Hepatocellular carcinoma in Japan (SC) (Ono Pharmaceutical pipeline, July 2017)
  • 01 Apr 2017 Ono Pharmaceutical completes a phase I trial in Hepatocellular carcinoma (Late-stage disease) in Japan (SC) (JapicCTI142477)
  • 28 Mar 2016 Phase-I development is ongoing in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top